A phase I/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumours

被引：4
|
作者：
Luke, J. J. [1 ]
Janku, F. [2 ]
Strauss, J. [3 ]
Olszanski, A. J. [4 ]
Leach, K. [5 ]
Radhakrishnan, I. [5 ]
Abbas, A. [5 ]
机构：
[1] UPMC Hillman Canc Ctr, Med, Pittsburgh, PA USA
[2] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA
[3] Mary Crowley Med Res Ctr, Oncol, Dallas, TX USA
[4] Fox Chase Canc Ctr, Med Oncol, Main Campus, Philadelphia, PA 19111 USA
[5] Spring Bank Pharmaceut, Oncol Dept, Hopkinton, MA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.712
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
598TiP
引用
收藏
页码：S500 / S500
页数：1
相关论文
共 50 条
  • [21] A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
    S Lheureux
    A M Oza
    S A Laurie
    R Halford
    D Jonker
    E Chen
    D Keller
    V Bourade
    L Wang
    L Doyle
    L L Siu
    R Goel
    British Journal of Cancer, 2015, 113 : 1534 - 1540
  • [22] A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
    Lheureux, S.
    Oza, A. M.
    Laurie, S. A.
    Halford, R.
    Jonker, D.
    Chen, E.
    Keller, D.
    Bourade, V.
    Wang, L.
    Doyle, L.
    Siu, L. L.
    Goel, R.
    BRITISH JOURNAL OF CANCER, 2015, 113 (11) : 1534 - 1540
  • [23] A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors
    Silk, Ann W.
    Saraiya, Biren
    Groisberg, Roman
    Chan, Nancy
    Spencer, Kristen
    Girda, Eugenia
    Shih, Weichung
    Palmeri, Marisa
    Saunders, Tracie
    Berman, Robert M.
    Coric, Vlad
    Chen, Suzie
    Zloza, Andrew
    Vieth, Joshua
    Mehnert, Janice M.
    Malhotra, Jyoti
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [24] A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors
    Ann W. Silk
    Biren Saraiya
    Roman Groisberg
    Nancy Chan
    Kristen Spencer
    Eugenia Girda
    Weichung Shih
    Marisa Palmeri
    Tracie Saunders
    Robert M. Berman
    Vlad Coric
    Suzie Chen
    Andrew Zloza
    Joshua Vieth
    Janice M. Mehnert
    Jyoti Malhotra
    European Journal of Medical Research, 27
  • [25] Phase Ib dose-escalation study of eribulin in combination with capecitabine in patients with advanced/metastatic cancer
    Savulsky, C.
    Nasim, M.
    Plummer, R.
    Evans, J.
    Morrison, R.
    Anthoney, A.
    Haney, S.
    Madi, A.
    Johnston, C.
    Carter, D.
    Reydermann, L.
    Gopalakrishna, P.
    Wanders, J.
    Twelves, C.
    ONKOLOGIE, 2012, 35 : 153 - 154
  • [26] A phase Ib dose-escalation study of TRC105 in combination with bevacizumab for advanced solid tumors
    Mendelson, David S.
    Rosen, Lee S.
    Robert, Francisco
    Chiorean, E. Gabriela
    Goldman, Jonathan Wade
    Seon, Ben K.
    Alvarez, Delia
    Adams, Bonne J.
    Theuer, Charles P.
    Leigh, Bryan R.
    Gordon, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors
    Lorusso, D.
    Fornari, G.
    Caponigro, F.
    Quirino, M.
    Merlano, M.
    Airoldi, M.
    Schena, M.
    Jannuzzo, M. G.
    Crippa, S.
    Scambia, G.
    EJC SUPPLEMENTS, 2007, 5 (04): : 111 - 112
  • [28] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Jeffrey R. Infante
    Roger B. Cohen
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Patricia M. LoRusso
    Investigational New Drugs, 2017, 35 : 576 - 588
  • [29] Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
    Isambert, Nicolas
    Freyer, Gilles
    Zanetta, Sylvie
    You, Benoit
    Fumoleau, Pierre
    Falandry, Claire
    Favier, Laure
    Assadourian, Sylvie
    Soussan-Lazard, Karen
    Ziti-Ljajic, Samira
    Trillet-Lenoir, Veronique
    CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1743 - 1750
  • [30] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Infante, Jeffrey R.
    Cohen, Roger B.
    Kim, Kevin B.
    Burris, Howard A., III
    Curt, Gregory
    Emeribe, Ugochi
    Clemett, Delyth
    Tomkinson, Helen K.
    LoRusso, Patricia M.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 576 - 588
12345